This site is intended for health professionals only

Pfizer and GSK merge HIV divisions

teaser

The HIV drug divisions of GlaxoSmithKline and Pfizer are to be combinedinto a new and as yet unnamed London-based R&D company.

It will be 85% owned by GSK, 15% by Pfizer, focus on the development of HIV treatments, have a 19% share of the market and projected sales of £1.6 billion.

It will also inherit a portfolio of 11 products, including GSK’s Combivir and Pfizer’s Selzentry, and a pipeline of six drugs under development.

The collaboration is the latest in a series of pharmaceutical-sector mergers that have been prompted by the global recession and falling sales, coupled with the arrival of cheap generic competition as global patents expire.

Article continues below this sponsored advert
Advertisement

US-based Pfizer recently announced the $68 billion (£45.6 billion) takeover of rival Wyeth, while Merck was acquired by Schering-Plough.

GSK says that while it does not envisage any similar mergers or takeovers, more Pfizer-style deals may be on the horizon.

Says boss Andrew Witty: “This marks a definitive step by GSK to renew our focus and deliver more medicines, more efficiently, to people living with HIV/Aids.”

Copyright Press Association 2009

Pfizer






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x